News

Pharmabiz2d
Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis
Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...
ZAWYA3d
Egypt, France deepen healthcare cooperation with four new agreements
The new agreements aim to enhance healthcare system efficiency in both countries and expand French investments in Egypt’s ...
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...
Sanofi Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people ...
Pharmabiz8d
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases: Paris Friday, April 4, 2025, 14:00 Hrs [IST] The US Foo ...
EuropaWire8d
FDA Grants Orphan Drug Status to Sanofi’s Rilzabrutinib: A New Hope for wAIHA, IgG4-RD, and Beyond
Rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation from the FDA for treating warm autoimmune hemolytic an ...
Medical Dialogues9d
USFDA grants orphan drug designation to Sanofi Rilzabrutinib for two rare diseases
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to ...
American Association of Individual Investors11d
Which Is a Better Investment, Corcept Therapeutics Incorporated or Sanofi Stock?
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 ...
PharmiWeb12d
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
finanzen14d
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Brian Foard Executive Vice President, Head of Specialty Care, Sanofi "This approval highlights our commitment to advancing innovation and improving care for the rare blood disorders community. Qfitlia ...
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of treatment administered every two months for patients with the rare blood clotting ...
U.S. News & World Report14d
US FDA Approves Sanofi's Bleeding Disorder Therapy
U.S.-listed shares of Paris-based Sanofi closed 1.7% higher. Sanofi's subcutaneous, or under-the-skin, therapy helps prevent bleeding and lowers antithrombin, a protein that delays blood clotting ...